Company Profile
MoonLake Immunotherapeutics Stock Price, News & Catalysts
- Ticker:
- MLTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
16.35 USD (-0.73%)
Close
Last updated: August 17, 2026
1.32B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, MLTX closed down 0.73% at $16.35. No new same-company headline was identified in the current news window.
Company overview
Nanobody-Based Immunology
MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding.
Sonelokimab
Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting with albumin. MoonLake is developing the candidate across dermatology and rheumatology indications with substantial unmet need.
Hidradenitis Suppurativa
The VELA Phase 3 program evaluated sonelokimab in adults with hidradenitis suppurativa, while VELA-TEEN extends development into adolescents. The adult program supports the company's planned U.S. biologics-license application.
Psoriatic Arthritis
IZAR-1 and IZAR-2 are global Phase 3 studies in active psoriatic arthritis. IZAR-1 met all Week 16 clinical endpoints for the selected sonelokimab regimen, and IZAR-2 includes a standard-of-care comparator in patients who did not respond adequately to TNF inhibitors.
Additional Inflammatory Diseases
MoonLake is also studying sonelokimab in axial spondyloarthritis and preparing a clinical program in palmoplantar pustulosis, extending the franchise across multiple IL-17-driven diseases.
Future catalysts
- Completion of enrollment in the Phase 3 IZAR-2 psoriatic-arthritis study in the third quarter of 2026.
- Sonelokimab BLA submission for hidradenitis suppurativa by the end of September 2026.
- Initiation of enrollment in the palmoplantar-pustulosis program in the second half of 2026.
- FDA assignment of a PDUFA date and decision on Priority Review for the hidradenitis-suppurativa BLA by the end of November 2026.
- Results from the P-OLARIS psoriatic-arthritis/axial-spondyloarthritis study at the end of 2026 or in early 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics (MLTX) most recently closed at 16.35 USD, a -0.73% move versus the previous session.
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics currently has a market capitalization of 1.32B USD on BioPharmSignal.
What does MoonLake Immunotherapeutics do?
Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting with albumin. MoonLake...
On which exchange is MLTX stock listed?
MoonLake Immunotherapeutics (MLTX) is associated with NASDAQ, Switzerland, Biopharma.
What is IL-17A?
Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting with albumin.
Which conditions is MoonLake Immunotherapeutics targeting with IL-17A?
MoonLake Immunotherapeutics is associated with immunology, dermatology based on its company overview and current catalyst commentary.
How does MoonLake Immunotherapeutics describe recent progress with IL-17A?
Completion of enrollment in the Phase 3 IZAR-2 psoriatic-arthritis study in the third quarter of 2026. Sonelokimab BLA submission for hidradenitis suppurativa by the end of September 2026. Initiation of enrollment in the palmoplantar-pustulosis program in the second half of 2026. FDA assignment of a PDUFA date and decision on Priority Review for the...
What is IL-17F?
Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting with albumin.